Lamberto Andreotti - Bristol Myer CEO, Director

BMYMP -- USA Stock  

USD 1,054  195.48  15.64%

  CEO
Mr. Lamberto Andreotti is no longer a NonExecutive Chairman of the Board of BristolMyers Squibb Company effective as of May 2nd, 2017. He has served as Executive Chairman of the Board of the Company from May 5, 2015 to August 3, 2015. He is no longer Chief Executive Officer of the Company effective May 5, 2015. He was Chief Executive Officer, Director of BristolMyers Squibb Company. Mr. Andreotti was Chief Executive Officer since May 2010. He was our President and Chief Operating Officer from March 2009 to May 2010. From March 2008 to March 2009, Mr. Andreotti served as Executive Vice President and Chief Operating Officer of BMS. From May 2007 until March 2008, he served as Executive Vice President of BMS and Chief Operating Officer of Worldwide Pharmaceuticals, a division of BMS
Age: 64  CEO Since 2015      
212-546-4000  http://www.bms.com
Andreotti served as Executive Vice President of BMS and President of Worldwide Pharmaceuticals from 20052007 and as Senior Vice President and International President of Worldwide Pharmaceuticals from 20022005. He is a member of Pharmaceutical Research and Manufacturers of America and The Business Council.

Lamberto Andreotti Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 10.68 % which means that it generated profit of $10.68 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 2.97 % meaning that it generated $2.97 on every $100 dollars invested by stockholders.
The company has accumulated 7.39 B in total debt with debt to equity ratio (D/E) of 59.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bristol Myer Squi has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Found 12 records

CEO Since

Robert OrtbergUnited Technologies Corporation
2018
Geraud DarnisUnited Technologies Corporation
2013
John StankeyATT
2019
Noriko GunjiCanon
2018
Brian LesserATT
2017
Ralph VegaATT
2015
Andrew GeisseATT
2012
Judith MarksUnited Technologies Corporation
2019
Gregory HayesUnited Technologies Corporation
2016
Lori LeeATT
2017
Jeffery McElfreshATT
2019
Thaddeus ArroyoATT
2017

Entity Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.Bristol Myer Squi Pf [BMYMP] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Bristol Myer Squi Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, CFO, Executive Vice President
Gerald Storch, Independent Director
Louis Schmukler, President - Global Manufacturing and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
John Elicker, Senior Vice President - Public Affairs and Investor Relations
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President Controller
Giovanni Caforio, COO, Director
Vicki Sato, Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Joseph Caldarella, Senior Vice President Corporate Controller
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, CEO, Director
Thomas Lynch, Independent Director
Dinesh Paliwal, Independent Director
Lewis Campbell, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Senior Vice President - Global Human Resources
Sandra Leung, General Counsel, Corporate Secretary
Paul Autenried, Senior Vice President - Enterprise Services, CIO
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President Head - Business Development
Peter Arduini, Independent Director

Stock Performance Indicators

Current Sentiment - BMYMP

Bristol Myer Squi Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in Bristol Myer Squi Pf. What is your opinion about investing in Bristol Myer Squi Pf? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Bristol Myer Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myer and Canon. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Search macroaxis.com